Standard nutrition support for malnourished nasopharyngeal cancer patients
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 study tests whether giving a standard nutrition plan can improve nutritional status and outcomes in people with locally advanced nasopharyngeal cancer who are malnourished. It mainly checks whether nutrition support helps you tolerate treatment and do better over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- New diagnosis of nasopharyngeal cancer (WHO type II or III) within the study timeframe
- Age 18 to 65, and you are able to do your usual activities fairly well (Karnofsky 80 or higher)
- Cancer stage is III to IVa, and it has not spread to distant organs
- You have current blood-test results that meet minimum levels (blood counts and organ enzymes)
- No major problems with digestion, hormones, heart, lungs, kidneys, or liver
- You have not had cancer treatment yet (no radiation, chemotherapy, or other anti-cancer therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial compares two treatment plans for newly diagnosed, operable nasopharyngeal cancer: adding surgery plus targeted chemoradiation versus standard chemoradiation alone. It aims to see whether the surgery-based plan improves control of the cancer and related outcomes.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.